Zobrazeno 1 - 10
of 24
pro vyhledávání: '"N G Tyurina"'
Autor:
E A Baryakh, N G Tyurina, V I Vorobyev, E G Gemdzhyan, Ya K Mangasarova, G A Klyasova, A M Kovrigina, T N Obukhova, E E Zvonkov, M A Vernyuk, A M Chervontseva, Yu Yu Polyakov, А Е Misyurina, T T Valiev, V A Zherebtsova, A U Magomedova, G M Galstyan, K V Yatskov, E S Nesterova, A I Vorobyev, S K Kravchenko
Publikováno v:
Терапевтический архив, Vol 87, Iss 7, Pp 4-14 (2015)
Aim. To evaluate the efficiency and toxicity of the intensive Burkitt’s lymphoma (BL) therapy protocol BL-M-04. Subjects and methods. A total of 70 patients diagnosed with BL, including 45 men and 25 women whose age was 15 to 62 years (median age 3
Externí odkaz:
https://doaj.org/article/298e63f168c2470392a0b2cc5db43d82
Autor:
L P Mendeleeva, V G Savchenko, N G Tyurina, E Yu Varlamova, K S Momotyuk, L S Lyubimova, E O Gribanova, E N Ustinova, O S Pokrovskaya, N E Mitish, V A Zherebtsova, I B Kaplanskaya, I A Vorob'ev, E M Gretsov, N N Kalinin
Publikováno v:
Современная онкология, Vol 8, Iss 1, Pp 55-57 (2006)
Целесообразность применения высокодозной химиотерапии при ММ обсуждается с начала 80-х годов прошлого столетия, когда T.J. McElvain и R.L. Powles с
Externí odkaz:
https://doaj.org/article/fe502a6ed3c54510b8658f6aa666f288
Publikováno v:
Онкогематология, Vol 8, Iss 4, Pp 18-23 (2014)
Due to the relative low incidence of primary mediastinal B-large cell lymphoma (PM BLCL) optimal approaches to its treatment is still not well developed. Possibility to improve PM BLCL clinical outcomes by intensifying induction chemotherapy (CT) and
Externí odkaz:
https://doaj.org/article/92ced134509c4f979192382fbc36a309
Autor:
N. V. Zhukov, A. L. Uss, N. F. Milanovich, V. V. Ptushkin, B. V. Afanasyev, N. B. Mikhaylova, V. B. Larionova, E. A. Demina, E. E. Karamanesht, N. G. Tyurina, O. A. Pavlova, A. G. Rumyantsev, A. D. Kaprin
Publikováno v:
Онкогематология, Vol 8, Iss 3, Pp 35-41 (2014)
Traditionally, the concern of fatal complication is a major obstacle to transfer patients with unfavorable course of Hodgkin’s lymphoma tonational transplantation centers. Early mortality after high-dose chemotherapy with autologous hematopoietic s
Externí odkaz:
https://doaj.org/article/f6115523b8514ec88678b6e2d7768b68
Publikováno v:
Issledovaniâ i Praktika v Medicine, Vol 4, Iss 1, Pp 49-57 (2017)
The review summarizes the results of studies of levels and/or activity in the blood serum of a metabolic marker thymidine kinase-1 (TK-1) of proliferating cells in patients with lymphoproliferative diseases (LPD) and malignant neopasms (NM). Comparis
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 9, Iss 1, Pp 6-12 (2016)
Background & Aims. Lactate dehydrogenase (LDH) and b2-microglobulin (b2-MG) are usually detected as serological tumor markers (TM) in malignant lymphoproliferative diseases (LPD); however, their use in monitoring of chemotherapy (CT) is limited due t
Autor:
N. V. Zhukov, A. L. Uss, N. F. Milanovich, V. V. Ptushkin, B. V. Afanasiev, N. B. Mikhaylova, V. B. Larionova, Ye. A. Demina, N. G. Tyurina, M. A. Vernyuk, Ye. Ye. Karamanesht, A. G. Rumyantsev
Publikováno v:
Onkogematologiâ, Vol 9, Iss 3, Pp 32-40 (2015)
The influence of previous antitumor therapy the efficacy and tolerability of high-dose chemotherapy with autologous hematopoietic progenitor cells transplantation (HCST) in 369 patients with Hodgkin, s lymphoma in the clinics of Russia and CIS countr
Publikováno v:
Klinicheskaia laboratornaia diagnostika. 62(8)
The purpose of study: To determine possibilities of complex morphological diagnostic (routine cytology and histology, immunocytochemistry and immunohistochemistry, molecular genetics) of lymphoma of marginal zone. The study included 10 patients with
Autor:
N. V. Zhukov, A. L. Uss, N. F. Milanovich, V. V. Ptushkin, B. V. Afanasiev, N. B. Mikhaylova, V. B. Larionova, E. A. Demina, N. G. Tyurina, M. A. Vernyuk, E. E. Karamanesht, A. G. Rumyantsev
Publikováno v:
Onkogematologiâ, Vol 9, Iss 2, Pp 37-44 (2014)
Autologous hematopoietic stem cell transplantation (HSCT) is the standard treatment for patients with relapsed and primary refractoryHodgkin's lymphoma (HL). According to current recommendations HSCT must be performed in first relapse or after regist
Autor:
I. V. Kolobaev, A. M. Chervontseva, Kh. S. Kosumova, M. A. Vernyuk, I. B. Kaplanskaya, N. G. Tyurina
Publikováno v:
Onkologiya. Zhurnal imeni P.A.Gertsena. 6:48